EDP 323
Alternative Names: EDP-323Latest Information Update: 16 Feb 2026
At a glance
- Originator Enanta Pharmaceuticals
- Class Antivirals; Small molecules
- Mechanism of Action RNA-dependent RNA polymerase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Respiratory syncytial virus infections
Most Recent Events
- 16 Feb 2026 EDP 323 is still in phase-I trials for Respiratory-syncytial-virus-infections in USA (PO)
- 28 Oct 2025 No recent reports of development identified for phase-I development in Respiratory-syncytial-virus-infections(In volunteers) in USA (PO)
- 20 Oct 2025 Updated antimicrobial, adverse events and efficacy data from a phase-IIa trial in Respiratory syncytial virus infections (In volunteers) released by Enanta Pharmaceuticals